Abstract
Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Current Pharmaceutical Design
Title:Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants
Volume: 19 Issue: 40
Author(s): Shervin Liddie, Mara A. Balda and Yossef Itzhak
Affiliation:
Keywords: Adolescence, adulthood, cocaine, conditioned place preference, dopamine, methamphetamine, neurotoxicity, nitric oxide (NO), psychostimulant, sensitization.
Abstract: Abuse of psychostimulants presents a significant health and social problem worldwide. Traditionally, the dopaminergic system has received much attention for its role in the development and manifestation of addictive behavior. The identification of the close interaction between the dopaminergic and glutamatergic pathway and by extension the nitric oxide (NO) signaling pathway (the nitrergic system) have provided a broader scope on the mechanisms underlying the development of addictive behavior following exposure to cocaine and methamphetamine. NO signaling is associated with the acquisition and maintenance of several behavioral phenotypes induced by cocaine and methamphetamine (METH), as well as in METH-induced dopaminergic depletion. Because it appears that NO signaling influences response to reward, memory formation, and free radical-induced neurotoxicity, pharmacotherapies targeting NO signaling pathway may prove beneficial in the treatment of psychostimulants abuse.
Export Options
About this article
Cite this article as:
Liddie Shervin, Balda A. Mara and Itzhak Yossef, Nitric Oxide (NO) Signaling as a Potential Therapeutic Modality Against Psychostimulants, Current Pharmaceutical Design 2013; 19 (40) . https://dx.doi.org/10.2174/138161281940131209144527
DOI https://dx.doi.org/10.2174/138161281940131209144527 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alert Cell Strategy: Mechanisms of Inflammatory Response and Organ Protection
Current Pharmaceutical Design Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Current Pharmaceutical Design Bothrops pauloensis Snake Venom Toxins: The Search for New Therapeutic Models
Current Topics in Medicinal Chemistry Molecular Basis of the Anti-Inflammatory Effects of Terpenoids
Inflammation & Allergy - Drug Targets (Discontinued) Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Giardiasis: Recent Progress in Chemotherapy and Drug Development (Hot Topic: Anti-Infective Agents Executive Editors: Mitchell A. Avery / Vassil St.) Georgiev
Current Pharmaceutical Design Nitric Oxide, Aspirin-Triggered Lipoxins and NO-Aspirin in Gastric Protection
Inflammation & Allergy - Drug Targets (Discontinued) Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System
CNS & Neurological Disorders - Drug Targets Ion Channel Screening Technology
CNS & Neurological Disorders - Drug Targets On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry The ASK1-MAP Kinase Signaling in ER Stress and Neurodegenerative Diseases
Current Molecular Medicine Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets Evaluating Quinacrine as a Potential Amyloid Imaging Compound: Studies on Hen Egg White Lysozyme as Model System
Protein & Peptide Letters Plasma-Rich in Growth Factor and its Clinical Application
Current Stem Cell Research & Therapy Studies of Plasmacytoid Dendritic Cell Dynamics in Simian Immunodeficiency Virus Infection of Nonhuman Primates Provide Insights into HIV Pathogenesis
Current HIV Research Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design Role of Granulocyte-colony Stimulating Factor in the Protection of Cerebral Vascular Endothelium, White Matter, and Cognition
Current Neurovascular Research Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology